Rite Aid Corporation (RAD)
(Delayed Data from NYSE)
$8.77 USD
-0.03 (-0.34%)
Updated May 3, 2019 04:02 PM ET
After-Market: $8.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.77 USD
-0.03 (-0.34%)
Updated May 3, 2019 04:02 PM ET
After-Market: $8.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Rite Aid (RAD) Q3 Loss Narrower Than Expected, Revenues Down
by Zacks Equity Research
Rite Aid's (RAD) Q3 results reflect the impacts of drab demand in flu immunizations and COVID-19 vaccines. Also, management updates its fiscal 2023 view.
Rite Aid (RAD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of 56.25% and 2.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's How Rite Aid (RAD) is Placed Just Ahead of Q3 Earnings
by Zacks Equity Research
Higher non-COVID prescriptions, strength in PBM and the expansion of delivery services are likely to Rite Aid's (RAD) Q3 results amid sluggishness in the Retail Pharmacy and Pharmacy Services segments.
Costco (COST) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Costco (COST) delivered earnings and revenue surprises of -1.27% and 0.42%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Rite Aid (RAD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed at $5.16 in the latest trading session, marking a -1.34% move from the prior day.
Rite Aid (RAD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed the most recent trading day at $5.25, moving -0.94% from the previous trading session.
Rite Aid (RAD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed at $5.91 in the latest trading session, marking a -1.83% move from the prior day.
Rite Aid (RAD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed the most recent trading day at $5.49, moving -0.54% from the previous trading session.
Rite Aid (RAD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Rite Aid (RAD) closed at $5.14, marking a -1.53% move from the previous day.
Online Strength to Drive Rite Aid (RAD) Amid Supply-Chain Woes
by Zacks Equity Research
Rite Aid (RAD) remains well-placed on online strength, increased non-COVID prescriptions and cost initiatives despite muted COVID-19 testing and vaccine demand, and supply-chain issues.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon's
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon's are part of Zacks Industry Outlook article.
3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Challenges
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain from the growing demand for digital healthcare support. However, reimbursement challenges are hurting overall industry health.
Rite Aid (RAD) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Rite Aid (RAD) posts lower Q2 revenues from the year-ago fiscal quarter's level due to sluggishness in both the Retail Pharmacy and Pharmacy Services segments.
Rite Aid (RAD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of -36.96% and 0.66%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Factors Likely to Decide Rite Aid's (RAD) Fate in Q2 Earnings
by Zacks Equity Research
Rite Aid's (RAD) Q2 performance is likely to have been hurt by low COVID vaccine and testing demand. Strength in PBM, digital expansion and higher non-COVID prescriptions are expected to have aided.
Tilly's (TLYS) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Tilly's (TLYS) delivered earnings and revenue surprises of -18.75% and 1.45%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Rite Aid (RAD) Moves 7.9% Higher: Will This Strength Last?
by Zacks Equity Research
Rite Aid (RAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rite Aid (RAD) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Rite Aid's (RAD) Q1 results gain from higher sales of non-COVID-19 prescriptions and continued momentum at Elixir. Management raises its revenue guidance for fiscal 2023.
Rite Aid (RAD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of 14.29% and 5%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
What is Likely to Drive Rite Aid's (RAD) Earnings in Q1?
by Zacks Equity Research
Strong underlying business and robust digital and retail growth are expected to aid Rite Aid (RAD) in Q1. Its Retail Pharmacy segment is likely to be a key contributor despite supply headwinds.
Signet (SIG) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Signet (SIG) delivered earnings and revenue surprises of 24.89% and 1.62%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Vera Bradley (VRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vera Bradley (VRA) delivered earnings and revenue surprises of -18.75% and 11.69%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Cracker Barrel Old Country Store (CBRL) Beats Q3 Earnings Estimates
by Zacks Equity Research
Cracker Barrel (CBRL) delivered earnings and revenue surprises of 6.61% and 0.03%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Rite Aid (RAD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
Rite Aid (RAD) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Rite Aid's (RAD) Q4 results gains from growth in the Retail Pharmacy unit. Also, management issued an upbeat fiscal 2023 view.